Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|March 1, 2017

Eppendorf

We Know Bioprocessing
By exploiting the strong synergies in bioreactor technology and polymer manufacturing, Eppendorf has emerged as a global player in the bioprocess marketplace. With a comprehensive offering of single-use and traditional products for the growth of mammalian and microbial cells, and working volumes of 60 mL–2400 L, the Eppendorf bioprocess portfolio can satisfy the demands of process development through production.

Eppendorf
INTERPHEX Booth #3639

Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.